Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes

Standard interventions for glioma include surgery, radiation and chemotherapies but the prognosis for malignant cases such as glioblastoma multiforme remain grim. Even with targeted therapeutic agent, bevacitumab, malignant glioma often develops resistance and recurrence. Thus, developing alternativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Li, Su, Yu-Kai, Lin, Chien-Min, Chao, Tsu-Yi, Huang, Shang-Pen, Huynh, Thanh-Tuan, Jan, Hsun-Jin, Whang-Peng, Jacqueline, Chiou, Jeng-Fong, Wu, Alexander T.H., Hsiao, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342527/
https://www.ncbi.nlm.nih.gov/pubmed/27564106
http://dx.doi.org/10.18632/oncotarget.11572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342527/
https://www.ncbi.nlm.nih.gov/pubmed/27564106
http://dx.doi.org/10.18632/oncotarget.11572

Ejemplares similares